Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.

Biochimica et Biophysica Acta-Gene Regulatory Mechanisms, published by Elsevier, stands as a premier academic journal within the realms of biochemistry, biophysics, genetics, and molecular biology. With an impressive Q1 category ranking across several disciplines and a commendable Scopus percentile ranking of 89th in its field, the journal is a significant contributor to the scientific community, promoting groundbreaking research and discoveries from 2008 to 2024. Although it does not currently operate under an open access model, researchers accessing this journal will find in-depth articles that advance understanding of gene regulatory mechanisms and their implications for health and disease. The journal's location in the Netherlands enriches its global perspective, attracting a diverse range of submissions that reflect the cutting edge of science today. By publishing high-quality, peer-reviewed research, Biochimica et Biophysica Acta-Gene Regulatory Mechanisms continues to foster knowledge and innovation, making it an essential resource for researchers, professionals, and students alike seeking to delve deeper into the molecular underpinnings of life.

CELL BIOLOGY AND TOXICOLOGY, published by SPRINGER, stands as a vital journal within the realms of cell biology and toxicology, boasting an impressive 2023 Q1 ranking in its fields, alongside robust Scopus rankings placing it in the top 11th percentile for Toxicology and the 22nd for Health, Toxicology and Mutagenesis. With an ISSN of 0742-2091 and an E-ISSN of 1573-6822, the journal has been a cornerstone of scientific discourse since its inception in 1984, and will continue to converge innovative research until 2024. The journal focuses on the interplay between cellular mechanisms and toxicological implications, making it an essential resource for researchers, healthcare professionals, and students keen on advancing their understanding of these critical areas. Although it does not offer open access, its high impact and prestigious standing ensure that its publications reach a wide audience dedicated to significant advancements in the life sciences.

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS is a vital academic journal published by Taylor & Francis Inc, dedicated to the intricate and evolving domains of biochemistry, genetics, and molecular medicine. With an ISSN of 1525-7770 and E-ISSN of 1532-2335, this journal aims to provide a comprehensive platform for the dissemination of research findings, reviews, and methodologies related to nucleosides, nucleotides, and nucleic acids. As a research journal thriving since its inception in 2000, it reflects a diverse spectrum of studies crucial for advancing knowledge in biochemistry (ranked Q4) and genetics (Q4), while also achieving Q3 status in medicine (miscellaneous). Despite its current standing in the quartiles and Scopus rankings indicative of an emergent trajectory, the journal retains significant relevance for those delving into interdisciplinary research that intersects these fields. Researchers, professionals, and students alike can explore a plethora of original research articles, thought-provoking reviews, and updates on pioneering advances that shape our understanding of molecular biology. With its unwavering commitment to scholarly excellence, NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS continues to be an essential resource for those aiming to contribute to and stay informed about this pivotal area of scientific inquiry.

Reports of Biochemistry and Molecular Biology, published by VARASTEGAN INST MEDICAL SCIENCES, is a distinguished open access journal dedicated to advancing the fields of biochemistry and molecular biology. Since its inception in 2012, the journal has fostered a platform for researchers and professionals to disseminate their findings, contributing to a richer understanding of biochemical processes and molecular mechanisms. With a focus on innovative research and technology, the journal has established itself as a significant resource within its field, being classified in the Q3 category for Biochemistry and Molecular Biology by 2023. Notably, it has achieved respectable Scopus rankings, including a rank of #40/72 in Biochemistry (medical) as well as a common ground across multiple related categories. The journal’s commitment to open access ensures that its valuable content is freely available to the global scientific community, facilitating knowledge sharing among students, researchers, and professionals alike. Located in Mashhad, Iran, Reports of Biochemistry and Molecular Biology serves as a bridge between cutting-edge research and practical applications in the biochemistry and molecular biology domains.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

FUNCTIONAL & INTEGRATIVE GENOMICS, published by Springer Heidelberg, is a leading journal in the fields of genetics and molecular biology. Established in 2000, it serves as a pivotal platform for advancing our understanding of genomic functionality and integration, making significant contributions to both basic and applied research in genetics. With a robust impact factor and a ranking in the Q3 quartile for Genetics and Q2 for Medicine (Miscellaneous), the journal aims to publish innovative research that explores the relationships between genomic data and biological functions, appealing to a diverse audience of researchers and professionals. Although it operates under a subscription model, the journal's extensive archives remain a valuable resource for academics seeking to stay abreast of the latest findings and methodologies in genomics. As the field evolves, FUNCTIONAL & INTEGRATIVE GENOMICS remains committed to fostering scholarly dialogue and the dissemination of groundbreaking studies that influence future research trajectories.